FSP-peptide–major histocompatibility complex complex on antigen-presenting cell (null (no established standard abbreviation for this multi-component surface molecular entity))

Peptide–major histocompatibility complex (MHC) complexes on antigen-presenting cells are cell-surface protein complexes that present intracellularly- or extracellularly-derived peptides to T-cell receptors, enabling adaptive immune surveillance and T-cell activation[3][4][5][6]. MHC molecules are highly polymorphic glycoproteins: - MHC class I complexes are found on all nucleated cells and present peptides (typically 8–10 amino acids) derived from intracellular proteins, enabling recognition by cytotoxic T cells (CD8+)[1][4][6][7]. - MHC class II complexes are restricted to professional antigen-presenting cells (e.g., dendritic cells, macrophages, B cells) and present longer peptides (13–18 amino acids) from extracellular sources, recognized by helper T cells (CD4+)[5][4]. The specific sequence and structure of the peptide–MHC complex, as well as the presenting MHC allele, dictate immune recognition and underlie individual responses to pathogens, cancer neoantigens, and autoantigens[3][4][5]. The stability and composition of the complex determine its functional immunogenicity, and differences in the peptide or MHC allele can profoundly affect disease susceptibility and therapeutic outcomes. The designation "FSP-peptide–MHC complex" implies a particular peptide ("FSP") bound to a specific MHC molecule, forming a complex presented on the antigen-presenting cell. For unambiguous scientific and clinical use, the peptide sequence, length, and MHC allele should be specified. Note: The term as written is imprecise, and should be revised for data structuring or therapeutic development.

Other names

Peptide–MHC complexPeptide–HLA complex (in humans)Antigenic peptide-MHC complexpMHC complexPeptide–MHC class I complex (if class I)Peptide–MHC class II complex (if class II)Antigen-presenting cell surface pMHC complex

T-cell receptor (TCR) binding, triggering T-cell activation or cytotoxicity TCR-mimic biologics may block, enhance, or redirect T-cell recognition Peptide vaccines induce formation of specific pMHC complexes for immune activation